Objective: To explore the clinical effects of leukotriene modulators and salmeterol in the treatment of patients with bronchial asthma and their effects on patients with fractional exhaled nitric oxide (FeNO) and serum interleukine-10 (IL-10). ) And high-sensitive C-reactive protein (hs-CRP) levels. Methods: Sixty patients with bronchial asthma who were treated in our hospital from March 2019 to March 2020 were selected and divided into study group and control group (30 patients in each group) according to the random number table method. Patients in the control group received salmeterol treatment, and patients in the study group were treated with leukotriene modifiers on the basis of the control group. The levels of FeNO, serum IL-10, hs-CRP, and forced exhalation in the first second were compared between the two groups before and after treatment. Changes in the percentage of forced expiratory volume in predicted value (FEV 1 %), peak expiratory flow (PEF) and asthma control test (ACT) and adverse effects during treatment The occurrence of the reaction. Results: After treatment, the FeNO and serum hs-CRP levels in the study group were significantly lower than those in the control group, and the serum IL-10 levels, FEV 1 %, PEF and ACT were significantly higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Conclusion: Leukotriene modifier combined with salmeterol has a good therapeutic effect on bronchitis and asthma. It can significantly improve the inflammatory state of the patient's body, while regulating the lung function of the patient, and the treatment is safer. [ABSTRACT FROM AUTHOR]